The form was uploaded to medical-data-models.org - Original URL: https://medical-data-models.org/13676
StudyName: Eligibility Multiple Sclerosis NCT00001669
Date of export from the portal: 02.07.2020
Date of Upload / last change: 27.02.2016
License: Creative Commons BY 4.0

----

Description: 
A 48-Week (24-Week Baseline Followed by a 24-Week Treatment) Phase II Pilot Study of the Tolerability and Effect/Efficacy of Subcutaneously Administered Insulin-Like Growth Factor-1 (rhIGF) (CEP-151) in Multiple Sclerosis (MS) Patients; ODM derived from: https://clinicaltrials.gov/show/NCT00001669
